PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.
By: Snehal Dabir, Amy Kluge, Karen McColl, Yu Liu, Minh Lam, Balazs Halmos, Gary Wildey, Afshin Dowlati

Division of Hematology and Oncology, Case Western Reserve University, Cleveland, Ohio 44106.
2013-1-9; doi: 10.1002/ijc.28448
Abstract

Protein inhibitor of activated STAT3 (PIAS3) is an endogenous inhibitor of STAT3 that negatively regulates STAT3 transcriptional activity and cell growth and demonstrates limited expression in the majority of human squamous cell carcinomas of the lung. In the present study we sought to determine if PIAS3 inhibits cell growth in non-small cell lung cancer (NSCLC) cell lines by inducing apoptosis. Our results demonstrate that over-expression of PIAS3 promotes mitochondrial depolarization, leading to cytochrome c release, caspase 9 and 3 activation and PARP cleavage. This intrinsic pathway activation was associated with decreased Bcl-xL expression and increased Noxa expression and was independent of p53 status. Furthermore, PIAS3 inhibition of STAT3 activity was also p53 independent. Microarray experiments were performed to discover STAT3-independent mediators of PIAS3-induced apoptosis by comparing the apoptotic gene expression signature induced by PIAS3 over-expression with that induced by STAT3 siRNA. The results showed that a subset of apoptotic genes was uniquely expressed only after PIAS3 expression. Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy as well as its potential to synergize with Bcl-2 targeted inhibitors. © 2013 Wiley Periodicals, Inc.



Copyright © 2013 UICC.

PMID:23959540






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements